Relative adrenal insufficiency in patients with chronic liver disease: What do we know and how is it relevant in critical care medicine

Clinical Pulmonary Medicine

Volumn 17, Issue 5, 2010, Pages 232-238

  Arabi, Yaseen M ^a   Al Dorzi, Hasan M ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

adrenal insufficiency; cortisol; critical illness; liver cirrhosis; sepsis

Indexed keywords

CYTOKINE; ETOMIDATE; FLUCONAZOLE; FLUDROCORTISONE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 6; ITRACONAZOLE; KETOCONAZOLE; LIPOPOLYSACCHARIDE; NORADRENALIN; PRASTERONE; PRASTERONE SULFATE; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL GLAND; ADRENAL INSUFFICIENCY; CHRONIC LIVER DISEASE; CRITICAL ILLNESS; DIAGNOSTIC TEST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMICS; HOSPITAL INFECTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FAILURE; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYCOSIS; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN BLOOD LEVEL; REVIEW; SURVIVAL; VASCULAR RESISTANCE;

EID: 77957774554     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e3181ef9ede     Document Type: Review

References (81)

1. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data for 2003. Natl Vital Stat Rep. 2005;53:1-48.
2. Vashist Y, Semela D, Dufour JF. Hyperdynamic circulation in liver cirrhosis: desensitization of vasoconstrictive receptors by G protein-coupled receptor kinases. Med Hypotheses. 2004;62:82-85.
3. Newby DE, Hayes PC Hyperdynamic circulation in liver cirrhosis: not peripheralvasodilatationbut 'splanchnic steal.' QJM. 2002;95:827-830.
4. Arkenau HT, Stichtenoth DO, Frolich JC, et al. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters ofhyperdynamic circulation. ZGastroenterol. 2002;40:907-913.
5. Gaenzer H, Sturm W, Neumayr G, et al. Hyperdynamic circulation in liver cirrhosis: no evidence for peripheral vasodilation detected by ultrasound of the brachial artery. Am J Gastroenterol. 2000;95:551-552.
6. Campillo B, Bories PN, Benvenuti C, et al. Serum and urinary nitrate levels in liver cirrhosis: endotoxemia, renal function and hyperdynamic circulation. J Hepatol. 1996;25:707-714.
7. Li CP, Lee FY, Tsai YT, et al. Plasma interleukin-8 levels in patients with post-hepatitic cirrhosis: relationship to severity ofliver disease, portal hyper-tension and hyperdynamic circulation. J Gastroenterol Hepatol. 1996;11: 635-640.
8. Arabi Y, Ahmed QA, Haddad S, et al. Outcome predictors of cirrhosis patients admitted to the intensive care unit. Eur J Gastroenterol Hepatol. 2004;16:333-339.
9. Arabi Y, Haddad S, Goraj R, et al. Assessment of performance of four mortality prediction systems in a Saudi Arabian intensive care unit. Crit Care. 2002;6:166-174.
10. Bouachour G, Tirot P, Varache N, et al. Hemodynamic changes in acute adrenal insufficiency. Intensive Care Med. 1994;20:138-141.
11. Marik PE, Gayowski T, Starzl TE. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med. 2005;33:1254-1259.
12. Zietz B, Lock G, Plach B, et al. Dysfunction of the hypothalamic- pituitary-glandular axes and relation to child-Pugh classification in male patients with alcoholic andvirus-related cirrhosis. Eur J Gastroenterol Hepatol. 2003;15: 495-501.
13. Harry R, Auzinger G, Wendon J. The clinical importance ofadrenal insuf-ficiency in acute hepatic dysfunction. Hepatology. 2002;36:395-402.
14. Harry R, Auzinger G, Wendon J. The effects ofsupraphysiological doses of corticosteroids in hypotensive liver failure. Liver Int. 2003;23:71-77
15. du Cheyron D, Bouchet B, Cauquelin B, et al. Hyperreninemic hypoaldosteron-ism syndrome, plasma concentrations ofinterleukin-6 and outcome in critically ill patients with liver cirrhosis. Intensive Care Med. 2008;34:116-124.
16. Arabi Y, Al Jumah A, Dabbagh O, et al. Hydrocortisone for cirrhotic patients with septic shock: double-blind placebo-controlled randomized trial. Am J Resp Crit Care Med. 2008;179:A1561.
17. Fernandez J, Escorsell A, Zabalza M, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology. 2006;44:1288-1295.
18. Tsai MH, Peng YS, Chen YC, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43:673-681.
19. Marik PE. Adrenal-exhaustion syndrome in patients with liver disease. Intensive Care Med. 2006;32:275-280.
20. Marik PE. Mechanisms and clinical consequences of critical illness associ-ated adrenal insufficiency. Curr Opin Crit Care. 2007;13:363-369.
21. Mc Donald JA, Handelsman DJ, Dilworth P, et al. Hypothalamic-pituitary adrenal function in end-stage non-alcoholic liver disease. J Gastroenterol Hepatol. 1993;8:247-253.
22. Prigent H, Maxime V, Annane D. Science review: mechanisms ofimpaired adrenal function in sepsis and molecular actions of glucocorticoids. Crit Care. 2004;8:243-252.
23. Yaguchi H, Tsutsumi K, Shimono K, et al. Involvement of high density lipoprotein as substrate cholesterol for steroidogenesis by bovine adrenal fasciculoreticularis cells. Life Sci. 1998;62:1387-1395.
24. Cicognani C, Malavolti M, Morselli-Labate AM, et al. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepa-titis. Arch Intern Med. 1997;157:792-796.
25. Kovacs KA, Lam YM, Pater JL. Bilateral massive adrenal hemorrhage. Assessment of putative risk factors by the case-control method. Medicine (Baltimore). 2001;80:45-53.
26. Trevisani F, Bernardi M, De Palma R, et al. Circadian variation in renal sodium and potassium handling in cirrhosis. The role ofaldosterone, cortisol, sympathoadrenergic tone, and intratubular factors. Gastroenterology. 1989; 96:1187-1198.
27. Gines P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl JMed. 2004;350:1646-1654.
28. Fernandez-Esparrach G, Guevara M, Sort P, et al. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A random-ized double-blind trial ofspironolactone versus placebo. J Hepatol. 1997;26: 614-620.
29. Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl JMed. 2009;360:2328-2339.
30. Oberbeck R, Dahlweid M, Koch R, et al. Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. Crit Care Med. 2001;29:380-384.
31. Kaymakoglu S, Okten A, Cakaloglu Y, et al. Hypogonadism is not related to the etiology ofliver cirrhosis. J Gastroenterol. 1995;30:745-750.
32. Dunn JF, Nisula BC, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticoste-roid-binding globulin in human plasma. J Clin Endocrinol Metab. 1981;53: 58-68.
33. Hammond GL, Smith CL, Paterson NA, et al. A role for corticosteroid- binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab. 1990;71:34-39.
34. Hamrahian AH, Oseni TS, Arafah BM. Measurements ofserum free cortisol in critically ill patients. N Engl JMed. 2004;350:1629-1638.
35. Arlt W, Allolio B. Adrenal insufficiency. Lancet. 2003;361:1881-1893.
36. Venkataraman S, Munoz R, Candido C, et al. The hypothalamic-pituitary- adrenal axis in critical illness. Rev Endocr Metab Disord. 2007;8:365-373.
37. Tait AS, Dalton M, Geny B, et al. The large clostridial toxins from Clostrid-ium sordellii and C difficile repress glucocorticoid receptor activity. Infect Immun. 2007;75:3935-3940.
38. Webster JI, Sternberg EM. Anthrax lethal toxin represses glucocorticoid receptor (GR) transactivation by inhibiting GR-DNA binding in vivo. Mol Cell Endocrinol. 2005;241:21-31.
39. Wu JY, Hsu SC, Ku SC, et al. Adrenal insufficiency in prolonged critical illness. Crit Care. 2008;12:R65.
40. Guzman JA, Guzman CB. Adrenal exhaustion in septic patients with vaso-pressor dependency. J Crit Care. 2007;22:319-323.
41. Rasaratnam B, Kaye D, Jennings G, et al. The effect ofselective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A ran-domized trial. Ann Intern Med. 2003;139:186-193.
42. Mookerjee RP, Sen S, Davies NA, et al. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut. 2003;52:1182-1187.
43. Pinsky MR, Vincent JL, Deviere J, et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest. 1993;103:565-575.
44. Tilg H, Wilmer A, Vogel W, et al. Serum levels ofcytokines in chronic liver diseases. Gastroenterology. 1992;103:264-274.
45. Llorent L, Richaud-Patin Y, Alcocer-Castillejos N, et al. Cytokine gene expression in cirrhotic and non-cirrhotic human liver. J Hepatol. 1996;24: 555-563.
46. Brunetti L, Preziosi P, Ragazzoni E, et al. Effects of lipopolysaccharide on hypothalamic-pituitary-adrenal axis in vitro. Life Sci. 1994;54:PL165-PL171.
47. Vishnyakova TG, Bocharov AV, Baranova IN, et al. Binding and internal-ization oflipopolysaccharide by Cla-1, a human orthologue ofrodent scav-enger receptor B1. JBiol Chem. 2003;278:22771-22780.
48. Baranova I, Vishnyakova T, Bocharov A, et al. Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. Infect Immun. 2002;70:2995-3003.
49. Jaattela M, Ilvesmaki V, Voutilainen R, et al. Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and ste-roidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology. 1991;128:623-629.
50. Ettinger WH, Varma VK, Sorci-Thomas M, et al. Cytokines decrease apoli-poprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb. 1994;14:8-13.
51. Ali M, Allen HR, Vedeckis WV, et al. Depletion of rat liver glucocorti-coid receptor hormone-binding and its mRNA in sepsis. Life Sci. 1991; 48:603-611.
52. Scammell JG, Denny WB, Valentine DL, et al. Overexpression of the FK506-binding immunophilin FKBP51 is the common cause ofglucocorti-coid resistance in three new world primates. Gen Comp Endocrinol. 2001; 124:152-165.
53. Molijn GJ, Spek JJ, van Uffelen JC, et al. Differential adaptation ofglucocor-ticoid sensitivity ofperipheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab. 1995;80:1799-1803.
54. Liu LY, Sun B, Tian Y, et al. Changes ofpulmonary glucocorticoid receptor and phospholipase A2 in sheep with acute lung injury after high dose endotoxin infusion Am Rev Respir Dis. 1993;148(4 Pt 1):878-881.
55. Molijn GJ, Koper JW, van Uffelen CJ, et al. Temperature-induced down-regulation of the glucocorticoid receptor in peripheral blood mononuclear leucocyte in patients with sepsis or septic shock. Clin Endocrinol (Oxf). 1995;43:197-203.
56. Melby JC, Spink WW. Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection JClin Invest. 1958;37:1791-1798.
57. Davies TH, Ning YM, Sanchez ER. A new first step in activation of steroid receptors: hormone-induced switching ofFKBP51 and FKBP52 immunophi-lins. JBiol Chem. 2002;277:4597-4600.
58. Turnbull AV, Rivier CL. Regulation ofthe hypothalamic-pituitary-adrenal axis by cytokines: actions andmechanisms of action Physiol Rev. 1999;79:1-71.
59. van Enckevort FH, Sweep CG, Span PN, et al. Reduced adrenal response to bacterial lipopolysaccharide in interleukin-6-deficient mice. J Endocrinol Invest. 2001;24:786-795.
60. van Enckevort FH, Sweep CG, Span PN, et al. Reduced adrenal response and increased mortality after systemic Klebsiella pneumoniae infection in inter-leukin-6-deficient mice. Eur Cytokine Netw. 2001;12:581-586.
61. Soni A, Pepper GM, Wyrwinski PM, et al. Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am JMed. 1995;98:266-271.
62. Gordon BR, Parker TS, Levine DM, et al. Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med. 2001;29:1563-1568.
63. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993;77:1690-1694.
64. Pariante CM, Pearce BD, Pisell TL, et al. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and func-tion. Endocrinology. 1999;140:4359-4366.
65. Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose ofetomidate. Anaesthesia. 1999;54:861-867.
66. Shibata S, Kami M, Kanda Y, et al. Acute adrenal failure associated with fluconazole after administration of high-dose cyclophosphamide. Am J He-matol. 2001;66:303-305.
67. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College ofCritical Care Medicine. Crit Care Med. 2008;36:1937-1949.
68. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med. 2003;31:141-145.
69. Siraux V, De Backer D, Yalavatti G, et al. Relative adrenal insufficiency in patients with septic shock: comparison of low-dose and conventional corti-cotropin tests. Crit Care Med. 2005;33:2479-2486.
70. Widmer IE, Puder JJ, Konig C, et al. Cortisol response in relation to the severity ofstress and illness. J Clin Endocrinol Metab. 2005;90:4579-4586.
71. de Jong MF, Beishuizen A, Spijkstra JJ, et al. Relative adrenal insufficiency as a predictor of disease severity, mortality, and beneficial effects of corti-costeroid treatment in septic shock. Crit Care Med. 2007;35:1896-1903.
72. Annane D, Sebille V, Charpentier C, et al. Effect oftreatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288:862-871.
73. Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect ofsteroids on survival and shock during sepsis depends on the dose. Ann Intern Med. 2004;141:47-56.
74. Bellissant E, Annane D. Effect of hydrocortisone on phenylephrine-mean arterial pressure dose-response relationship in septic shock. Clin Pharmacol Ther. 2000;68:293-303.
75. Bollaert PE, Charpentier C, Levy B, et al. Reversal oflate septic shock with supraphysiologic doses ofhydrocortisone. Crit Care Med. 1998;26:645-650.
76. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27:723-732.
77. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. NEngl JMed. 2008;358:111-124.
78. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guide-lines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-873. (Pubitemid 38344143)
79. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296-327.
80. Dhatariya K, Bigelow ML, Nair KS. Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabe-tes. 2005;54:765-769.
81. Dhatariya KK. Is there a role for dehydroepiandrosterone replacement in the intensive care population? Intensive Care Med. 2003;29:1877-1880.